JP2016518355A5 - - Google Patents

Download PDF

Info

Publication number
JP2016518355A5
JP2016518355A5 JP2016507587A JP2016507587A JP2016518355A5 JP 2016518355 A5 JP2016518355 A5 JP 2016518355A5 JP 2016507587 A JP2016507587 A JP 2016507587A JP 2016507587 A JP2016507587 A JP 2016507587A JP 2016518355 A5 JP2016518355 A5 JP 2016518355A5
Authority
JP
Japan
Prior art keywords
neo
mutation
sequences
encoded
neoplasm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016507587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518355A (ja
JP6702855B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/033185 external-priority patent/WO2014168874A2/en
Publication of JP2016518355A publication Critical patent/JP2016518355A/ja
Publication of JP2016518355A5 publication Critical patent/JP2016518355A5/ja
Priority to JP2020000367A priority Critical patent/JP7489193B2/ja
Application granted granted Critical
Publication of JP6702855B2 publication Critical patent/JP6702855B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016507587A 2013-04-07 2014-04-07 個別化された新生物ワクチンの組成物及び方法 Active JP6702855B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020000367A JP7489193B2 (ja) 2013-04-07 2020-01-06 個別化された新生物ワクチンの組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361809406P 2013-04-07 2013-04-07
US61/809,406 2013-04-07
US201361869721P 2013-08-25 2013-08-25
US61/869,721 2013-08-25
PCT/US2014/033185 WO2014168874A2 (en) 2013-04-07 2014-04-07 Compositions and methods for personalized neoplasia vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020000367A Division JP7489193B2 (ja) 2013-04-07 2020-01-06 個別化された新生物ワクチンの組成物及び方法

Publications (3)

Publication Number Publication Date
JP2016518355A JP2016518355A (ja) 2016-06-23
JP2016518355A5 true JP2016518355A5 (enExample) 2019-07-18
JP6702855B2 JP6702855B2 (ja) 2020-06-03

Family

ID=50842334

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016507587A Active JP6702855B2 (ja) 2013-04-07 2014-04-07 個別化された新生物ワクチンの組成物及び方法
JP2020000367A Active JP7489193B2 (ja) 2013-04-07 2020-01-06 個別化された新生物ワクチンの組成物及び方法
JP2022070352A Pending JP2022105069A (ja) 2013-04-07 2022-04-21 個別化された新生物ワクチンの組成物及び方法
JP2025061873A Pending JP2025106390A (ja) 2013-04-07 2025-04-03 個別化された新生物ワクチンの組成物及び方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020000367A Active JP7489193B2 (ja) 2013-04-07 2020-01-06 個別化された新生物ワクチンの組成物及び方法
JP2022070352A Pending JP2022105069A (ja) 2013-04-07 2022-04-21 個別化された新生物ワクチンの組成物及び方法
JP2025061873A Pending JP2025106390A (ja) 2013-04-07 2025-04-03 個別化された新生物ワクチンの組成物及び方法

Country Status (10)

Country Link
US (2) US20160101170A1 (enExample)
EP (1) EP2983702A2 (enExample)
JP (4) JP6702855B2 (enExample)
KR (3) KR102858313B1 (enExample)
CN (4) CN118557711A (enExample)
AU (5) AU2014251207B2 (enExample)
BR (1) BR112015025460B1 (enExample)
CA (2) CA3137846A1 (enExample)
IL (2) IL282202B2 (enExample)
WO (1) WO2014168874A2 (enExample)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
HRP20250981T1 (hr) 2011-05-24 2025-10-24 BioNTech SE Individualizirana cjepiva protiv raka
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
AU2014251207B2 (en) * 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN106132432A (zh) * 2013-12-06 2016-11-16 博德研究所 用于瘤形成疫苗的配制品
JP7060324B2 (ja) * 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
JP7044551B2 (ja) 2014-09-10 2022-03-30 ジェネンテック, インコーポレイテッド 免疫原性変異体ペプチドスクリーニングプラットフォーム
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
EP4636401A2 (en) 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
US10307491B2 (en) 2015-01-30 2019-06-04 The Regents Of The University Of Michigan Liposomal particles comprising biological molecules and uses thereof
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
EP3268012A4 (en) 2015-03-12 2018-10-31 Health Research, Inc. Enrichment of cd16+ monocytes to improve dendritic cell vaccine quality
EP4537906A3 (en) * 2015-03-25 2025-08-20 The Regents of the University of Michigan Compositions and methods for delivery of biomacromolecule agents
EP3075389A1 (en) * 2015-03-31 2016-10-05 Technische Universität München T cell receptors and peptides derived by mutations for the treatment of cancer
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
JP7236216B2 (ja) 2015-04-23 2023-03-09 ナントミクス,エルエルシー がんのネオエピトープ
HUE052106T2 (hu) * 2015-04-27 2021-04-28 Cancer Research Tech Ltd Eljárás rák kezelésére
AU2016258845B2 (en) * 2015-05-01 2022-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
EP3294324A1 (en) 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
TW202241500A (zh) * 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
JP2018535202A (ja) * 2015-10-12 2018-11-29 ナントミクス,エルエルシー ネオエピトープの反復発見と適応可能な免疫療法およびその方法
KR20180083327A (ko) * 2015-10-12 2018-07-20 난토믹스, 엘엘씨 바이러스성 암 네오에피토프를 위한 조성물 및 방법
JP2018532736A (ja) 2015-10-12 2018-11-08 ナントミクス,エルエルシー チェックポイント阻害物質への感受性を予測するmsiおよびネオエピトープの探索のための系、組成物、および方法
EP3362929B1 (en) * 2015-10-12 2020-08-12 Nantomics, LLC Viral neoepitopes and uses thereof
TWI733719B (zh) 2015-12-07 2021-07-21 美商河谷控股Ip有限責任公司 改善的組合物及用於新表位之病毒遞送的方法及其應用
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
AU2017205270B2 (en) 2016-01-08 2024-01-18 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
KR20180102707A (ko) * 2016-02-11 2018-09-17 난트 홀딩스 아이피, 엘엘씨 듀얼 타겟팅을 통한 아데노바이러스의 피하 전달
EP3414692A4 (en) 2016-02-12 2020-07-29 Nantomics, LLC HIGH-RATE IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES
SG11201807770RA (en) 2016-03-24 2018-10-30 Nantcell Inc Sequence arrangements and sequences for neoepitope presentation
EP3446119A1 (en) * 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
JP7033549B2 (ja) 2016-05-04 2022-03-10 フレッド ハッチンソン キャンサー リサーチ センター 細胞に基づくネオ抗原ワクチンおよびその使用
AU2017281389B2 (en) 2016-06-20 2024-02-22 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
EP3471778A4 (en) 2016-06-20 2020-02-19 The Regents of The University of Michigan COMPOSITIONS AND METHODS FOR ADMINISTERING BIOMACROMOLECULAR AGENTS
AU2017299162B2 (en) * 2016-07-20 2024-09-26 BioNTech SE Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
US10350280B2 (en) 2016-08-31 2019-07-16 Medgenome Inc. Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
EP3535423B1 (en) * 2016-11-07 2022-01-05 The United States of America, as represented by the Secretary, Department of Health and Human Services Methods for selecting therapy for a cancer patient
MX2019006010A (es) * 2016-11-23 2019-12-05 Gritstone Oncology Inc Administracion viral de neoantigenos.
WO2018102613A2 (en) * 2016-12-01 2018-06-07 Nantomics, Llc Tumor antigenicity processing and presentation
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2018183544A1 (en) * 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Method for identification of retained intron tumor neoantigens from patient transcriptome
JP7155470B2 (ja) * 2017-03-31 2022-10-19 エーシーティー ジェノミックス (アイピー) カンパニー リミテッド 免疫原性がん特異的エピトープのためのランク付けシステム
US20210113673A1 (en) * 2017-04-19 2021-04-22 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
JP7051898B2 (ja) 2017-04-24 2022-04-11 ナントセル,インコーポレイテッド 標的型ネオエピトープベクター及びそのための方法
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
CN110996970A (zh) 2017-06-02 2020-04-10 亚利桑那州立大学董事会 创建个性化癌症疫苗的方法
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
AU2018279627B2 (en) * 2017-06-09 2023-08-10 Seattle Project Corp. Neoantigen identification, manufacture, and use
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
KR102684237B1 (ko) * 2017-06-21 2024-07-11 트랜스진 개인 맞춤형 백신
US20200140813A1 (en) * 2017-06-22 2020-05-07 Tcer Ab T-cell expansion method and uses
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
AU2018326799A1 (en) 2017-08-31 2020-02-27 Modernatx, Inc. Methods of making lipid nanoparticles
EP3679578A4 (en) * 2017-09-05 2021-06-30 Gritstone Oncology, Inc. NEOANTIGEN IDENTIFICATION FOR T-CELL THERAPY
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
EP3688165A4 (en) * 2017-09-25 2021-09-29 Nant Holdings IP, LLC VALIDATION OF THE PRESENTATION OF NEOEPITOPES
ES3029080T3 (en) 2017-10-10 2025-06-23 Seattle Project Corp Neoantigen identification using hotspots
EP3706765A4 (en) 2017-11-07 2021-07-14 Coimmune, Inc. METHODS AND USES FOR DENDRITIC CELL THERAPY
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
TWI727232B (zh) * 2017-12-01 2021-05-11 大陸商上海桀蒙生物技術有限公司 個人化癌症疫苗的製備方法
WO2019122050A1 (en) 2017-12-22 2019-06-27 Isa Pharmaceuticals B.V. Methods of immunization
CN108491689B (zh) * 2018-02-01 2019-07-09 杭州纽安津生物科技有限公司 基于转录组的肿瘤新抗原鉴定方法
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CA3100974A1 (en) * 2018-05-25 2020-11-28 The Wistar Institute Tumor-specific neoantigens and methods of using the same
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3813848A4 (en) * 2018-06-27 2022-07-20 ModernaTX, Inc. EPITOPE SELECTION FOR PERSONALIZED CANCER VACCINE
WO2020020444A1 (en) * 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
IL280112B2 (en) 2018-07-26 2025-11-01 Curevac Netherlands B V Cancer vaccines for breast cancer
EP3826669A2 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Off-the-shelf cancer vaccines
JP7598315B2 (ja) * 2018-09-05 2024-12-11 エンエーセー オンコイミュニティ アクスイェ セルスカプ 併用療法用dnaワクチンを標的とするネオアンチゲン
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
CA3111903A1 (en) 2018-09-27 2020-04-02 Vaccibody As Method for selecting neoepitopes
CN109337873A (zh) * 2018-09-30 2019-02-15 北京鼎成肽源生物技术有限公司 一种lrff细胞
WO2020097291A1 (en) * 2018-11-07 2020-05-14 Modernatx, Inc. Rna cancer vaccines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
GB201821207D0 (en) 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy
CA3131777A1 (en) * 2019-03-01 2020-09-10 Flow Pharma Inc. Design, manufacture, and use of personalized cancer vaccines
US20220108768A1 (en) * 2019-03-08 2022-04-07 Nantomics, Llc System and method for variant calling
CN110059625B (zh) * 2019-04-18 2023-04-07 重庆大学 一种基于mixup的人脸训练与识别方法
EP3963335B1 (en) * 2019-05-03 2024-08-21 Epivax Therapeutics, Inc. Neoantigens in cancer
JP7457733B2 (ja) 2019-05-30 2024-03-28 グリットストーン バイオ インコーポレイテッド 改変アデノウイルス
EP3983008A4 (en) * 2019-06-11 2023-07-12 Iogenetics, LLC. NEOANTIGEN IMMUNOTHERAPIES
KR20220056847A (ko) * 2019-06-21 2022-05-06 커날 바이오로직스, 인크. 조작된 종양선택적 단백질 발현
CN110514845B (zh) * 2019-08-22 2022-09-27 深圳新合睿恩生物医疗科技有限公司 一种肿瘤新生抗原免疫原性检测方法及检测平台
CN116688107A (zh) * 2019-09-06 2023-09-05 北京微九九科技有限公司 一种肿瘤疫苗的制备方法及使用该方法制备的肿瘤疫苗
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
JP2022554395A (ja) * 2019-11-08 2022-12-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを処置するためのスプライシング由来抗原の同定
JP7496111B2 (ja) * 2019-12-24 2024-06-06 国立大学法人東京工業大学 サブキャリア変調方式テラヘルツレーダー
US11011253B1 (en) * 2020-07-09 2021-05-18 Brian Hie Escape profiling for therapeutic and vaccine development
EP4192496A4 (en) 2020-08-06 2025-01-01 Gritstone bio, Inc. MULTIEPITOP VACCINE CASSETTES
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
WO2022125507A1 (en) * 2020-12-07 2022-06-16 Iogenetics, Llc Personalized immunotherapies
WO2022125511A1 (en) * 2020-12-07 2022-06-16 Iogenetics, Llc Administration of anti-tumor vaccines
GB202104715D0 (en) 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
CN113069537A (zh) * 2021-04-29 2021-07-06 江苏欣生元生物科技有限公司 一种基于ras变异新生抗原表位的融合蛋白纳米疫苗及其制备方法
CN117321189A (zh) 2021-04-30 2023-12-29 泰根制药有限公司 淋巴细胞的单血管扩增
CN112972666B (zh) * 2021-05-12 2021-08-31 山东兴瑞生物科技有限公司 个性化基因修饰肿瘤dc疫苗的制备方法
US20220383996A1 (en) * 2021-05-27 2022-12-01 Amazon Technologies, Inc. Assigning peptides to peptide groups for vaccine development
US12537072B1 (en) 2021-05-27 2026-01-27 Amazon Technologies, Inc. Immunogenic response prediction based on major histocompatibility complex (MHC) data
WO2023043888A1 (en) * 2021-09-15 2023-03-23 Celloram Inc. Method of treating cancer
TW202340474A (zh) 2022-01-11 2023-10-16 大陸商深圳市珈鈺生物科技有限公司 樹突細胞腫瘤疫苗和其用途
EP4522728A1 (en) * 2022-05-11 2025-03-19 Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud Method of preparing and expanding a population of immune cells for cancer therapy, potency assay for tumor recognition, biological vaccine preparation and epitope target for antibodies
EP4598949A1 (en) 2022-10-07 2025-08-13 The General Hospital Corporation Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
JP2025541604A (ja) 2022-11-02 2025-12-22 ティゲン・ファーマ・ソシエテ・アノニム リンパ球の拡大
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
WO2024261339A1 (en) 2023-06-23 2024-12-26 Tigen Pharma Sa Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
CN120600110B (zh) * 2025-08-06 2025-12-09 上海交通大学医学院附属仁济医院 基于人工智能的多变病原t细胞表位精准筛选方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4210644A (en) 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US4226859A (en) 1979-06-07 1980-10-07 Velsicol Chemical Corporation Pyridyl esters of N-alkylidene-substituted phosphor- and phosphonamidic acids
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4743249A (en) 1986-02-14 1988-05-10 Ciba-Geigy Corp. Dermal and transdermal patches having a discontinuous pattern adhesive layer
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4906169A (en) 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4816540A (en) 1987-06-12 1989-03-28 Yasuhiko Onishi Cationic graft-copolymer
US5422119A (en) 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
AU625013B2 (en) 1989-11-03 1992-06-25 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US5198223A (en) 1990-10-29 1993-03-30 Alza Corporation Transdermal formulations, methods and devices
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5705190A (en) 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
EP1101490B1 (en) 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
US7283337B2 (en) 2005-03-04 2007-10-16 Headway Technologies, Inc. Abutted exchange bias design for sensor stabilization
CA2651796A1 (en) * 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
US9045556B2 (en) * 2007-02-07 2015-06-02 Nec Corporation Therapeutic agent for cancer
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
ES2608715T3 (es) * 2009-04-02 2017-04-12 Vaxon Biotech Identificación, optimización y uso de epítopos HLA-A24 crípticos para inmunoterapia
EP2569633B1 (en) * 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
HRP20250981T1 (hr) * 2011-05-24 2025-10-24 BioNTech SE Individualizirana cjepiva protiv raka
EP3511425A1 (en) * 2012-07-12 2019-07-17 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
AU2014251207B2 (en) * 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines

Similar Documents

Publication Publication Date Title
JP2016518355A5 (enExample)
Jain et al. Formulation and stabilization of recombinant protein based virus-like particle vaccines
CY1124202T1 (el) Εμβολια ανασυνδυασμενου zika
NZ721908A (en) Combination therapy with neoantigen vaccine
JP2014523406A5 (enExample)
JP2021501572A5 (enExample)
JP2015533841A5 (enExample)
CR20200492A (es) NUEVOS PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y SOPORTES PARA EL USO EN EL TRATAMIENTO INMUNOTERAPÉUTICO DE VARIOS TIPOS DE CÁNCER (Divisional 2018-174)
JP2018510215A5 (enExample)
EA201391109A1 (ru) Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования
MX2022000012A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
EP2413964A4 (en) VACCINE COMPOSITIONS AND METHODS OF USE
CR20200594A (es) NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA LA LEUCEMIA LINFOCÍTICA CRÓNICA (LLC) Y OTROS TIPOS DE CÁNCER (Divisional 2018-0295)
RU2015155821A (ru) Вакцины против малярии
JP2013507907A5 (enExample)
JP2018518457A5 (enExample)
MX2022007902A (es) Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia.
MX2019003615A (es) Proteina central y proteina del antigeno de superficie del virus de la hepatitis b y vacunas que comprenden estas.
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
CR20210066A (es) NUEVOS PÉPTIDOS Y ESTRUCTURAS DE SOPORTE PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CARCINOMA EPIDERMOIDE DE CABEZA Y CUELLO Y OTROS DE CÁNCER (Divisional 2019-0094)
EP4599845A3 (en) Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
CR20200637A (es) NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS COMO DIANAS Y PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE VESÍCULA BILIAR Y EL COLANGIOCARCINOMA, ASÍ COMO OTROS TIPOS DE CÁNCER (Divisional 2018-0591)
JP2014502961A5 (enExample)
JP2012516140A5 (enExample)
Caputo et al. Induction of humoral and enhanced cellular immune responses by novel core–shell nanosphere-and microsphere-based vaccine formulations following systemic and mucosal administration